Literature DB >> 9849469

Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33(7), 1141-1148.

P Limonta, G Pratesi, R M Moretti, M Montagnani Marelli, M Motta, D Dondi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9849469     DOI： 10.1016/s0959-8049(97)10143-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  3 in total

1.  Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline.

Authors:  C Yates; A Wells; T Turner
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

2.  Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.

Authors:  Stephan Seitz; Stefan Buchholz; Andrew Victor Schally; Florian Weber; Monika Klinkhammer-Schalke; Elisabeth C Inwald; Roberto Perez; Ferenc G Rick; Luca Szalontay; Florian Hohla; Sabine Segerer; Chui Wai Kwok; Olaf Ortmann; Jörg Bernhard Engel
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

Review 3.  Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.

Authors:  Fabrizio Fontana; Monica Marzagalli; Marina Montagnani Marelli; Michela Raimondi; Roberta M Moretti; Patrizia Limonta
Journal:  Int J Mol Sci       Date:  2020-12-14       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.